FDA Clears Cyperus Sperm Separation Device for Fertility Labs
Contrario Medical's single-use device uses a two-membrane design to prepare motile sperm from semen samples.
Contrario Medical's single-use device uses a two-membrane design to prepare motile sperm from semen samples.
The molecular test could help identify patients more likely to respond to abatacept, with early access expected in 2027.
A study of 60,449 lab results found that using broader screening thresholds doubled detection rates of primary aldosteronism compared to Endocrine Society guidelines, according to research in Hypertension.
Abbott has launched a next-generation Oncodetect MRD test that uses whole-genome sequencing to track up to 5,000 patient-specific cancer variants, offering a 30-fold increase in detection sensitivity, according to the company.
A Penn State-led team has developed a rapid syphilis test using multilayer nanoparticles, achieving up to 46% stronger signal intensity and enabling single-step detection of low antibody titers.
The 20-minute multiplex test delivers eight results covering bacterial vaginosis, Candida species, and trichomoniasis from clinician- or self-collected swabs.
Werfen has launched a web-based platform designed to centralize autoimmune testing data, automate workflows, and integrate with laboratory information systems for high-volume clinical labs.
Labcorp and Thrive Global have launched the Thrive 5 Health Test, a direct-to-consumer panel combining five cardiometabolic biomarkers with behavioral guidance, now available through Labcorp OnDemand.
The patent expands intellectual property coverage for the blood-based assay ahead of its planned commercial launch.
A multicenter study led by Children’s Hospital Colorado finds that skin biopsy fibroblast assays can help diagnose primary mitochondrial diseases, potentially reducing the need for invasive muscle and liver biopsies.
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
Tampa General Hospital is the first in the Southeast to implement the MeMed BV host-response test in its emergency workflow, reporting a 33% reduction in cefepime use and 13% fewer hospitalizations, according to hospital-led research.